Oral contraceptive usage and the expression of CA 15-3 and c-erbB-2 in the saliva of healthy women

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics

Volumn 88, Issue 6, 1999, Pages 687-690

  McIntyre, Raeline ^a   Bigler, Lenora ^a,b   Dellinger, Tracy ^a   Pfeifer, Mary ^a   Mannery, Tarah ^a   Streckfus, Charles ^a,c  

^a School of Dentistry   (United States)

^b Department of Medicine

^c UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 15-3 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ORAL CONTRACEPTIVE AGENT; SALIVA PROTEIN;

ADULT; ARTICLE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DRUG EFFECT; FEMALE; HUMAN; METABOLISM; REFERENCE VALUE; SALIVA;

ADULT; BREAST NEOPLASMS; CA-15-3 ANTIGEN; CONTRACEPTIVES, ORAL; FEMALE; HUMANS; RECEPTOR, ERBB-2; REFERENCE VALUES; SALIVA; SALIVARY PROTEINS;

EID: 0033252232     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1079-2104(99)70011-9     Document Type: Article

References (20)

1. Hannaford PC. Combined oral contraceptives: do we know all of their effects? Contraception 1995;51:325-7.
2. Vessey MP. Effect of endogenous and exogenous hormones on breast cancer: epidemiology. Verh Dtsch Ges Pathol 1997;81:493-501.
3. Ursin G, Ross RK, Sullivan-Halley J, Hanisch R, Henderson B, Bernstein L. Use of oral contraceptives and risk of breast cancer in young women. Breast Cancer Res Treat 1998;50:175-84.
4. Brinton LA, Brogan DR, Coates RJ, Swanson CA, Potischman N, Stanford JL. Breast cancer risk among women under 55 years of age by joint effects of usage of oral contraceptives and hormone replacement therapy. Menopause 1998;5:145-51.
5. Paul C, Skegg DC, Spears GF, Kaldor JM. Oral contraceptives and breast cancer: a national study. Br Med J 1986;293:723-6.
6. Murphy GP. Cancer statistics. CA-A Journal for Clinicians 1998;48:6-29.
7. Safi F, Kohler I, Rottinger E, Suhr P, Beger HG. Comparison of CA 15-3 and CEA in diagnosis and monitoring of breast cancer. Int J Biol Markers 1989;4:207-14.
8. Krainer M, Brodowicz T, Zeillinger R, Wiltschke C, Scholten C, Seifert M, et al. Tissue expression and serum levels of HER-2/neu in patients with breast cancer. Oncology 1997;54:475-81.
9. Molina R, Jo J, Filella X, Bruix J, Castells A, Hague M et al. Serum levels of c-erbB-2 (HER-2/neu) in patients with malignant and nonmalignant diseases. Tumor Biol 1997;18:188-96.
10. Sjögren S, Inganas M, Lindgren A, Holmberg L, Bergh J. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncology 1998;16:462-9.
11. Shalaby MR, Shepard HM, Presta L, Rodrigues ML, Beverley PC, Feldmann M, et al. Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells over-expressing the HER2 proto-oncogene. J Exp Med 1992;175:217-25.
12. Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fednly B, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997;151:1523-30.
13. Fehm T, Maimonis P, Katalinic A, Jager WH. The prognostic significance of c-erbB-2 serum proteins in metastatic breast cancer. Oncology 1998;55:33-8.
14. Fehm T, Maimonis R Weitz S, Teramoto Y, Katalinic A, Jager W. Influence of circulating c-erbB-2 serum proteins on response to adjuvant chemotherapy in node-positive breast cancer patients. Breast Cancer Res Treat 1997;43:87-95.
15. Tsuda H, Sakamaki C, Tsugane S, Fukutomi R, Hirohashi S. A prospective study of the significance of gene and chromosome alterations as prognostic indicators of breast cancer patients with lymph node metastases. Breast Cancer Res Treat 1998;48:21-32.
16. Molina R, Jo J, Filella X, Zanon G, Pahisa J, Munoz M, et al. CerbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value. Breast Cancer Res Treat 1998;51:109-19.
17. 1997 Update of recommendations for the use of tumor markers in breast and colorectal cancer. J Clin Oncology 1998;16:793-5.
18. Streckfus C, Bigler L, Tucci M, Thigpen J. The presence of CA 15-3, c-erbB-2, EGFR, Cathepsin-D, and p53 in saliva among women with breast carcinoma: a preliminary study. Cancer Invest 1999; 18. In press.
19. Navazesh M, Christensen C. A comparison of whole mouth resting and stimulated salivary measurements. J Dent Res 1982;61:1158-62.
20. Tampellini M, Berruti A, Gerbino A, Buniva T, Torta M, Gorzegno G, et al. Relationship between CA 15-3 serum levels an disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease. Br J Cancer 1997;75:698-702.